Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CALCITRIOL

All products: general benefit

Other products in the same Health Canada class (A11CC) — coverage varies; not interchangeable

  • Alfacalcidol (One-Alpha): general benefit

Calcitriol-Odan · DIN 02431637 · 0.25mcg · capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Calcitriol-Odan · DIN 02431637 Manufacturer: Odan Laboratories Ltd.; listing date 2016-03-30 Health Canada: Marketed since 2014-10-10 · brand CALCITRIOL-ODAN · ATC A11CC04 CALCITRIOL · form Capsule · route Oral · ingredients CALCITRIOL 0.25 MCG · company Odan laboratoriesltd · schedule Prescription
Check this DIN again · Health Canada product record

Calcitriol-Odan: Formulary list price $0.2341/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2341 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91612 · Verify on the e-Formulary ↗ (DIN 02431637)

Source record
DIN 02431637: Calcitriol-Odan Raw flags: sec3=Y Item: 881600005; group id 886; item number 2129; lccId None; manufacturer id ODN Source form: Cap; strength: 0.25mcg Recorded listing: General benefit Source prices (unrounded): $0.2341; ministry $0.2341 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02431637 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91612
Interchangeable products
PMS-Calcitriol · DIN 02495899 · $0.2341 Rocaltrol · DIN 00481823 · $0.2341 Taro-Calcitriol · DIN 02485710 · $0.2341
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (88:16 Vitamin D) and how they are covered

Matched class: 88:16 Vitamin D

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALFACALCIDOL Some products covered without a code (check the product listing): ERGOCALCIFEROL 88:16 Vitamin D

ALFACALCIDOL

· 5 products · General benefit · strengths: 0.25mcg, 1mcg, 2mcg/mL · Cap, Oral Drops

ERGOCALCIFEROL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 8288IU/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 88:16
Full class listing Related classes: 88:08 Vitamin B, 88:12 Vitamin C, 88:28 Multivitamins Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ROCALTROL (calcitriol capsules) is indicated in the management of:  Hypocalcemia and osteodystrophy in patients with chronic renal failure undergoing dialysis.  Hypocalcemia and its clinical manifestations associated with:  Post-surgical hypoparathyroidism.  Idiopathic hypoparathyroidism.  Pseudohypoparathyroidism.  Vitamin D resistant rickets (familial hypophosphatemia). Geriatrics (>65 years of age): Limited data are available in patients 65 years of age or older. Caution should be used when treating elderly patients. Pediatrics (<18 years of age): The safety and efficacy of calcitriol capsules in children have not been sufficiently investigated. Use is not recommended in this patient population. https://pdf.hres.ca/dpd_pm/00059786.PDF PM date: January 26, 2021 Source product: ROCALTROL; DIN 00481815; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Calcitriol (Sterimax Calcitriol Injection)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: See the ministry wording below; no separate indication heading is held.

Ministry criteria corpus 2025-01-01; page 247

Calcitriol Brand(s): Sterimax Calcitriol Injection DOSAGE FORM/ STRENGTH: 1 mcg/mL
Case-by-case funding is provided for dialysis patients. Please submit all relevant clinical data to enable an assessment by the EAP.
Calcitriol Injection, USP (calcitriol) 1mcg/mL Inj Sol – 1mL Pk (imported by STE) – Effective Date: July 17, 2024
This imported US product (PIN 09858344) is funded under the EAP on a temporary basis case by case and for those stabilized with an existing EAP approval. This is to manage a product shortage of calcitriol injection 1 mcg/mL (STE) DIN 02399334 that is funded under the EAP.
247

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.